Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages 551-564

  Caramuta, Stefano ^a,b   Lee, Linkiat ^a,b   Özata, Deniz M ^a,b   Akçakaya, Pinar ^a,b   Xie, Hong ^a,b   Höög, Anders ^b   Zedenius, Jan ^a,b   Bäckdahl, Martin ^a,b   Larsson, Catharina ^a,b   Lui, Weng Onn ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adrenocortical cancer; Diagnostic; Function; Over expression; TARBP2

Indexed keywords

DICER; PEPTIDES AND PROTEINS; PROTEIN DROSHA; PROTEIN TARBP2; UNCLASSIFIED DRUG;

ADOLESCENT; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; AGED; ARTICLE; CONTROLLED STUDY; DGCR8 GENE; DICER1 GENE; DROSHA GENE; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRKRA GENE; PROTEIN EXPRESSION; TARBP2 GENE;

ADRENOCORTICAL CANCER; DIAGNOSTIC; FUNCTION; OVER-EXPRESSION; TARBP2;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; DEAD-BOX RNA HELICASES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; RIBONUCLEASE III; RNA, MESSENGER; RNA-BINDING PROTEINS; YOUNG ADULT;

EID: 84882754577     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0098     Document Type: Article

References (51)

1. Ahlenstiel CL, Lim HG, Cooper DA, Ishida T, Kelleher AD & Suzuki K 2012 Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. Nucleic Acids Research 40 1579-1595. (doi:10.1093/nar/gkr891)
2. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037. (doi:10.1210/jc.2005-2639)
3. Beitzinger M, Peters L, Zhu JY, Kremmer E & Meister G 2007 Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biology 4 76-84. (doi:10.4161/rna.4.2.4640)
4. Benkirane M, Neuveut C, Chun RF, Smith SM, Samuel CE, Gatignol A & Jeang KT 1997 Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO Journal 16 611-624. (doi:10.1093/emboj/16.3.611)
5. Bertherat J, Groussin L & Bertagna X 2006 Mechanisms of disease: adrenocortical tumors - molecular advances and clinical perspectives. Nature Clinical Practice. Endocrinology & Metabolism 2 632-641. (doi:10.1038/ncpendmet0321)
6. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K & Shiekhattar R 2005 TRBP recruits the Dicer complex to Ago2 formicroRNA processing and gene silencing. Nature 436 740-744. (doi:10.1038/nature03868)
7. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW & Dacic S 2007 Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Research 67 2345-2350. (doi:10.1158/0008-5472.CAN-06-3533)
8. DeLellis RA, Lloyd RV, Heitz PU & Eng C 2004 Tumors of the adrenal gland. In World Health Organization Classification of Tumors. Pathology and Genetics of Endocrine Organs, 135-146. Lyon, France: IARC Press.
9. Faber C, Horst D, Hlubek F & Kirchner T 2011 Overexpression of Dicer predicts poor survival in colorectal cancer. European Journal of Cancer 47 1414-1419. (doi:10.1016/j.ejca.2011.01.006)
10. Flavin RJ, Smyth PC, Laios A, O'Toole SA, Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J et al. 2009 Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Modern Pathology 22 197-205. (doi:10.1038/modpathol.2008.135)
11. Forman JJ, Legesse-Miller A & Coller HA 2008 A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. PNAS 105 14879-14884. (doi:10.1073/pnas.0803230105)
12. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E et al. 2005 Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 90 1819-1829. (doi:10.1210/jc.2004-1075)
13. Fu X, Xue C, Huang Y, Xie Y & Li Y 2010 The activity and expression of microRNAs in prostate cancers. Molecular BioSystems 6 2561-2572. (doi:10.1039/c0mb00100g)
14. Gao ZH, Suppola S, Liu J, Heikkila P, Janne J & Voutilainen R 2002 Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 87 1170-1176. (doi:10.1210/jc.87.3.1170)
15. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F & Le Bouc Y 1994 Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 78 1444-1453. (doi:10.1210/jc.78.6.1444)
16. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M et al. 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research 61 6762-6767. (Pubitemid 32896498)
17. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G & Hammer G 2009 Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clinical Cancer Research 15 668-676. (doi:10.1158/1078-0432.CCR-08-1067)
18. Hammarstedt L, Muth A, Wangberg B, Bjorneld L, Sigurjonsdottir HA, Gotherstrom G, Almqvist E, Widell H, Carlsson S, Ander S et al. 2010 Adrenal lesion frequency: a prospective, cross-sectional CT study in a defined region, including systematic re-evaluation. Acta Radiologica 51 1149-1156. (doi:10.3109/02841851.2010.516016)
19. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Li Z et al. 2011 MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS ONE 6 e18286. (doi:10.1371/journal.pone.0018286)
20. Haussecker D & Proudfoot NJ 2005 Dicer-dependent turnover of intergenic transcripts from the human beta-globin gene cluster. Molecular and Cellular Biology 25 9724-9733. (doi:10.1128/MCB.25.21.9724-9733.2005)
21. Ilvesmaki V, Kahri AI, Miettinen PJ & Voutilainen R 1993 Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism 77 852-858. (doi:10.1210/jc.77.3.852)
22. Karginov FV, Conaco C, Xuan Z, Schmidt BH, Parker JS, Mandel G & Hannon GJ 2007 A biochemical approach to identifying microRNA targets. PNAS 104 19291-19296. (doi:10.1073/pnas.0709971104)
23. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T et al. 2005 Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Science 96 111-115. (doi:10.1111/j.1349-7006.2005.00015.x)
24. Kim DH, Villeneuve LM, Morris KV & Rossi JJ 2006 Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nature Structural & Molecular Biology 13 793-797. (doi:10.1038/nsmb1142)
25. Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J, Hoog A, Kjellman M, Lundeberg J, Hamberger B et al. 2009 Transcriptional profiling enables molecular classification of adrenocortical tumours. European Journal of Endocrinology 161 141-152. (doi:10.1530/EJE-09-0068)
26. Lee JY, Kim H, Ryu CH, Kim JY, Choi BH, Lim Y, Huh PW, Kim YH, Lee KH, Jun TY et al. 2004 Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. Journal of Biological Chemistry 279 30265-30273. (doi:10.1074/jbc. M312083200)
27. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X et al. 2011 Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clinical Cancer Research 17 1722-1730. (doi:10.1158/1078-0432. CCR-10-1800)
28. Ma Z, Swede H, Cassarino D, Fleming E, Fire A & Dadras SS 2011 Up-regulated Dicer expression in patients with cutaneous melanoma. PLoS ONE 6 e20494. (doi:10.1371/journal.pone.0020494)
29. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T et al. 2010 A microRNA targeting dicer for metastasis control. Cell 141 1195-1207. (doi:10.1016/j.cell.2010.05.017)
30. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, Rossi S, Fernandez AF, Carneiro F, Oliveira C et al. 2009 A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nature Genetics 41 365-370. (doi:10.1038/ng.317)
31. Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L et al. 2011 Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. PNAS 108 4394-4399. (doi:10.1073/pnas. 1014720108)
32. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM et al. 2008 Dicer, Drosha, and outcomes in patients with ovarian cancer. New England Journal of Medicine 359 2641-2650. (doi:10.1056/NEJMoa0803785)
33. Muralidhar B, Goldstein LD, Ng G, Winder DM, Palmer RD, Gooding EL, Barbosa-Morais NL, Mukherjee G, Thorne NP, Roberts I et al. 2007 Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. Journal of Pathology 212 368-377. (doi:10.1002/path.2179)
34. Özata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Höög A, Zedenius J, Backdahl M, Larsson C & Lui WO 2011 The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrine-Related Cancer 18 643-655. (doi:10.1530/ERC-11-0082)
35. Patterson EE, Holloway AK, Weng J, Fojo T & Kebebew E 2011 MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117 1630-1639. (doi:10.1002/cncr.25724)
36. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, Dousset B, Bertagna X, Clauser E & Bertherat J 2009 Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology 27 1108-1115. (doi:10.1200/JCO.2008.18.5678)
37. Roh MS, Kwak JY, Kim SJ, Lee HW, Kwon HC, Hwang TH, Choi PJ & Hong YS 2005 Expression of double-stranded RNA-activated protein kinase in small-size peripheral adenocarcinoma of the lung. Pathology International 55 688-693. (doi:10.1111/j.1440-1827.2005.01892.x)
38. Sand M, Gambichler T, Skrygan M, Sand D, Scola N, Altmeyer P & Bechara FG 2010 Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer. Cancer Investigation 28 649-653. (doi:10.3109/07357901003630918)
39. Sand M, Gambichler T, Sand D, Altmeyer P, Stuecker M& Bechara FG 2011 Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi. European Journal of Dermatology 21 18-21.
40. Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, Willscher E, Walz MK, Worm K & Schmid KW 2011 Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. Journal of Clinical Pathology 64 529-535. (doi:10.1136/jcp.2010.085621)
41. Schteingart DE 2007 Adjuvant mitotane therapy of adrenal cancer - use and controversy. New England Journal of Medicine 356 2415-2418. (doi:10.1056/NEJMe078087)
42. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG et al. 2009 miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clinical Cancer Research 15 7684-7692. (doi:10.1158/1078-0432.CCR-09-1587)
43. Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM & Demeure MJ 2008 Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Molecular Cancer Therapeutics 7 425-431. (doi:10.1158/1535-7163.MCT-07-0267)
44. Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, Nissan A, Cordon-Cardo C & Ghossein RA 2003 Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Modern Pathology 16 742-751. (doi:10.1097/01.MP.0000081730.72305.81)
45. Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Ando T, Mori R, Takashima N, Ogawa R et al. 2006 RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clinical Cancer Research 12 7322-7328. (doi:10.1158/1078-0432.CCR-06-0515)
46. Tombol Z, Szabo PM, Molnar V, Wiener Z, Tolgyesi G, Horanyi J, Riesz P, Reismann P, Patocs A, Liko I et al. 2009 Integrativemolecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocrine-Related Cancer 16 895-906. (doi:10.1677/ERC-09-0096)
47. Wang X, Wang J, Ma H, Zhang J & Zhou X 2011 Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Medical Oncology 29 919-927. (doi:10.1007/s12032-011-9880-5)
48. Weiss LM, Medeiros LJ & Vickery AL, Jr 1989 Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology 13 202-206. (doi:10.1097/00000478-198903000-00004)
49. Xie H, Zhao Y, Caramuta S, Larsson C & Lui WO 2012 miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS ONE 7 e46990. (doi:10.1371/journal.pone.0046990)
50. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP & Zhuang SM 2009 MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 50 113-121. (doi:10.1002/hep.22919)
51. Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Robertson CN, LaRocca R & Zbar B 1989 Genetic changes in human adrenocortical carcinomas. Journal of the National Cancer Institute 81 518-523. (doi:10.1093/jnci/81.7.518)